Symbiotec Pharmalab is a research-driven pharmaceutical and biotechnology company and a key player in corticosteroid and steroidal-hormone APIs, with FDA and EU-GMP approved manufacturing facilities.
Listed| Issue Size | ₹1,757 crore |
| Price Band | ₹938 – ₹988 |
| Lot Size | 15 shares |
| Open Date | 2026-08-24 |
| Close Date | 2026-08-27 |
| Allotment Date | 2026-08-28 |
| Listing Date | 2026-09-01 |
| Date | GMP | Implied Premium |
|---|---|---|
| 2026-09-01 | ₹185 | +18.72% |
| 2026-08-31 | ₹205 | +20.74% |
| 2026-08-27 | ₹285 | +28.85% |
| 2026-08-26 | ₹333 | +33.7% |
| 2026-08-24 | ₹409 | +41.4% |
| 2026-08-20 | ₹320 | +32% |
Applied for Symbiotec Pharmalab? Check whether shares were allotted to you directly on the official registrar site.
Symbiotec Pharmalab opens for subscription on August 24, 2026 and closes August 27, 2026.
The price band is ₹938 to ₹988 per share, valuing the company at about ₹6,244 crore at the upper end.
MUFG Intime India (the renamed Link Intime) is the registrar.
Symbiotec Pharmalab opened for subscription today, August 24, with grey market premium already strong at around ₹409 — a 41.4% implied premium over the ₹988 upper price band.
Last updated 2026-09-02T07:30:00+05:30
Grey market premium and listing estimates are informational, not investment advice, and can change quickly before listing. Data compiled from exchange filings, registrar disclosures and company announcements.